Research Material at the US and Canadian Border: Regulatory Status and What the Paperwork Has to Say

A shipment's regulatory status at the border is not settled by the phrase printed on the label. It is settled by two authorities applying two different tests, and a parcel has to satisfy both. Customs — U.S. Customs and Border Protection, or the Canada Border Services Agency — decides classification, valuation and entry: what the article is, what it is worth, and whether the declaration describing it is accurate. The health regulator — the FDA in the United States, Health Canada in Canada — decides admissibility: whether an article of that description may lawfully cross at all. A research-use-only designation speaks to the second question without answering it, because under both systems the regulatory character of an article is inferred from the whole record of how it is offered and described, not from one line of text ^[6][1].

What follows is the documentary shape of that, for a US or Canadian recipient: who decides, what the invoice must state, how classification works, what happens when a parcel is held, and how long the file survives afterwards. It is reference material, not legal advice, and the facts still in motion are flagged where they appear.

Two agencies, two tests: who decides whether a parcel enters

The division of labour is easy to state and constantly misunderstood. In the United States, CBP administers entry while the FDA holds the admissibility decision for articles within its jurisdiction; imports are presented to CBP, and where the FDA takes an interest the goods are held pending its determination ^[5]. In Canada the arrangement is formalised: CBSA assists Health Canada with the administration of the Food and Drugs Act at the border, and Health Canada determines admissibility. CBSA's own memorandum on the subject is blunt about where liability sits — importers are responsible for ensuring imported commodities comply with the applicable CBSA and Health Canada legislation, and importers may be held responsible for all costs relating to the movement, destruction, disposal or exportation of goods that Health Canada has deemed inadmissible ^[3].

Two practical consequences follow. First, Canadian declarations for regulated health commodities move through the Single Window Integrated Import Declaration, which carries Health Canada data elements alongside the customs data; missing or wrong elements can attract an Administrative Monetary Penalty independently of anything the health regulator decides ^[3]. Second, commercial importation of human drugs into Canada, including active ingredients, generally requires the importer to hold a Drug Establishment Licence or Site Licence — a status question about the importer, decided before any particular parcel is packed ^[3].

What "research use only" does, and what it cannot do

The US doctrine is codified. Under 21 CFR 201.128, "intended uses" refers to the objective intent of the persons legally responsible for the labelling of an article, and that intent may be shown by labelling claims, advertising matter, or oral or written statements — the label is one input among several, not the controlling one ^[6]. Health Canada's position is stated more directly still. In an April 2026 public advisory on unauthorized injectable peptides sold online, the department addressed the wording itself.

This type of labelling does not make these products legal or exempt from regulatory requirements.

Health Canada, public advisory on unauthorized injectable peptides, April 2026

That sentence is narrower than either side of the argument usually claims. It does not say research material is contraband. It says the phrase carries no exempting force — a designation cannot, by itself, move an article outside a definition it otherwise falls inside. What surrounds the designation is evidence. The same advisory records that Health Canada has seized unauthorized injectable peptide products and is working with CBSA to stop unauthorized shipments entering the country ^[1].

The 2026 Canadian enforcement line, and what it actually changed

On 11 June 2026 the Superior Court of Québec granted Health Canada a permanent injunction against an online retailer, Canlab Research, and its representatives, barring them from manufacturing, testing, distributing or selling unauthorized injectable peptides in Canada, or assisting others in doing so; the department announced the order publicly in late July ^[2]. It followed a run of seizures across 2025 and repeated earlier enforcement steps against the same seller ^[1][2].

Be careful about what that does and does not mean, because vendor commentary has been sloppy in both directions. An injunction binds named parties. It is not a regulation, it did not amend the Food and Drugs Act, and it created no new prohibition that was not already in the statute. What it changed is the evidentiary picture: it is a court-endorsed application of the existing definitions to online peptide sales, obtained rather than merely asserted, and it sits alongside a public advisory and an active border-cooperation arrangement ^[1][3]. For someone importing, the practical read is that the Canadian enforcement posture in this category is documented and current, and that the description on the paperwork will be read against it.

The commercial invoice: what the regulation actually requires

Most import problems that look like regulatory problems are documentation problems. The US invoice requirements are a closed list at 19 CFR 141.86, and they are more demanding than the one-line description most reagent invoices carry: the port of entry, the parties and timing of the sale or shipment, a detailed description of the merchandise including the name by which each item is known, the grade or quality, and the marks, numbers and symbols under which it is sold by the seller to the trade in the country of export, the quantities in appropriate weights and measures, the purchase price in the currency of the sale, itemised charges, the country of origin, and any goods or services furnished for production. The invoice must also state in adequate detail what is contained in each individual package, and must be in English or carry an accurate English translation ^[7].

The recurring failure is the description field. "Peptide", "chemical sample", "lab supplies" and "gift" are all inadequate under the regulation as written, and they generate holds because a description that could mean anything invites an officer to find out which thing it means ^[7]. Naming the substance, its form, its grade and the quantity present is both compliant and, in practice, faster.

HS classification, and why "choose the quieter code" is bad advice

Classification under the Harmonized System is a legal determination, not a preference. The General Rules of Interpretation govern it: classification follows the terms of the headings and the relevant section and chapter notes, applied to the goods as presented ^[13]. Several headings can genuinely be in play for peptide material, depending on what the article is and where a peptide stops counting as a peptide: Chapter 29 covers separate chemically defined organic compounds, with heading 2937 for hormones and their derivatives used primarily as hormones; heading 3504 covers peptones and other protein substances not elsewhere specified; and heading 3822 covers prepared diagnostic or laboratory reagents and certified reference materials ^[13].

Vendor pages circulate a specific piece of advice about this: that declaring under the reagent heading draws less scrutiny than declaring under the hormone heading, and is therefore the smarter choice. Treat that as what it is. Selecting a code to change the level of inspection rather than to describe the goods is a material false statement in the entry, and US law prices that exposure explicitly — 19 U.S.C. § 1592 prohibits entering merchandise by means of a document, statement or omission that is material and false, whether or not the government loses revenue, and grades penalties across three culpability tiers, with fraud exposed to a civil penalty up to the domestic value of the merchandise and gross negligence and negligence capped at multiples of the duty loss or, where duties are unaffected, at 40 percent and 20 percent of dutiable value ^[8]. Canada reaches the same conduct through its penalty system for inaccurate declarations ^[3].

De minimis: suspended in the US, narrow in Canada

This is the fastest-moving fact here, so take the date with it. Duty-free de minimis entry into the United States — the long-standing allowance for shipments valued at $800 or under — was suspended for all countries for goods entered for consumption on or after 29 August 2025; such shipments became subject to applicable duties, taxes and fees, with a separate treatment for goods moving through the international postal network ^[10]. The suspension rested on emergency economic powers, and in February 2026 the Supreme Court held that the same statute does not authorise the imposition of tariffs. The Court's decision did not itself resolve the legality of the de minimis suspension, and that question continued in the lower courts afterwards ^[11]. Anyone relying on the threshold for a shipment today should check current CBP guidance rather than any article, including this one.

Canada's arrangement is stable but narrower than most summaries suggest. Under CUSMA, courier shipments from the United States or Mexico are duty- and tax-free up to CAD 40, and duty-free but taxable above CAD 40 up to CAD 150; the low-value shipment threshold for streamlined accounting sits at CAD 3,300. Those commitments apply only to goods shipped by courier from the US or Mexico — other origins and other modes of transport fall outside them entirely ^[12]. None of these thresholds touch admissibility. A parcel can be under every value limit in both countries and still be refused, because value and legality are unrelated questions decided by different agencies.

If the parcel is held: the clocks that actually run

US procedure has real deadlines, and knowing them turns silence into a question you are entitled to have answered. Customs must issue a notice to the importer no later than five days, excluding weekends and holidays, after a decision to detain; merchandise not released within 30 days of presentation is deemed excluded by operation of law, which is the point at which an administrative protest becomes available ^[9]. Where the FDA is the deciding agency, the owner or consignee receives notice and has the right to appear and introduce testimony before a refusal of admission is finalised ^[5]. One provision deserves particular attention: since 2012 the FDA has been authorised to destroy a refused drug valued at $2,500 or less without offering the option to export it, subject to notice and an opportunity to present testimony first ^[5]. For small consignments that is often the whole story — there is no re-export to fall back on.

Import alerts are the mechanism that makes holds systematic rather than random. Import Alert 66-41 provides for detention without physical examination of unapproved new drugs promoted in the United States, listing named firms and products; a shipment caught by it is detained on paper, and the burden sits with the owner or consignee to present evidence that the shipment does not contain unapproved new drug products ^[4]. The alert is revised regularly — the current revision is dated May 2026 — so its contents are a live document rather than a fixed list ^[4]. Canada has no equivalent statutory deemed-exclusion clock; the admissibility determination is Health Canada's, and the costs of moving, destroying, disposing of or exporting inadmissible goods fall to the importer ^[3].

What the file has to hold afterwards

The import file outlives the shipment by years, and the retention periods are longer than most purchasers assume. US recordkeeping regulation requires records relating to an entry to be kept for five years from the date of entry, or five years from the date of the activity that generated the record ^[15]. Canada's runs longer and has a location condition attached: records relating to the origin, purchase, importation, cost, value, payment and disposal of commercial goods must be kept for six years following the year of importation, normally at a place of business in Canada unless the agency authorises otherwise ^[14]. Keep the invoice, transport document, entry number, classification used, any ruling relied on and broker correspondence together, filed against the same reference as the receiving record.

Where the public evidence is thin

Three honest limits, because the vendor content ranking for these terms states all three with a confidence nobody has earned. There is no published dataset giving detention or refusal rates for this commodity class at either border, so any figure quoted for the odds of a parcel being examined is invented; what is public is the mechanism, not the frequency. Classification outcomes are article-specific and turn on composition, presentation and packing, which is why the only reliable answer is a ruling on your facts rather than a code copied from a forum ^[13]. And the legal picture is genuinely in motion: the US de minimis position has changed twice within a year and remains subject to litigation ^[10][11], while the Canadian position rests on a departmental advisory and an injunction against a single named seller rather than on new legislation ^[1][2]. A document that tells you the position is simple and settled is telling you about its author, not about the border.